| heart failure | versus placebo or control No demonstrated result for efficacy Vesnarinone inferior to placebo in terms of Total mortality in VEST, 1998 Vesnarinone inferior to placebo in terms of Sudden death in VEST, 1998 | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| OPC-8212 MRG, 1990 | Vesnarinone vs placebo | | | Total mortality 0.00 [0.00; NaN] Worsening heart failure (requiring intervention) 0.14 [0.02; 1.12] Arrhythmia ∞ [NaN; ∞] Vertigo ∞ [NaN; ∞] | | VEST, 1998 | Vesnarinone vs placebo | | Total mortality 1.16 [1.02; 1.33] Sudden death 1.26 [1.03; 1.54] | Myocardial infarction (fatal & non fatal) 1.41 [0.51; 3.90] Cardiac death 1.13 [0.98; 1.30] Worsening heart failure (requiring intervention) 0.95 [0.85; 1.05] | | VSG, 1993 | Vesnarinone vs placebo | Total mortality 0.39 [0.21; 0.73] Sudden death 0.20 [0.06; 0.68] Cardiac death 0.36 [0.19; 0.68] Worsening heart failure (requiring intervention) 0.54 [0.31; 0.94] | | Myocardial infarction (fatal & non fatal) 1.00 [0.33; 3.04] Transplantation 0.46 [0.18; 1.19] Arrhythmia 2.99 [0.31; 28.52] |
| Trial | Treatments | Patients | Method |
|---|
| OPC-8212 MRG, 1990 | Vesnarinone 60mg/d (n=45) vs. placebo (n=48) | NYHA II-IV | double blind Parallel groups Sample size: 45/48 Primary endpoint: none FU duration: 3 months | | VEST, 1998 | Vesnarinone 30, 60mg/d (n=2550) vs. placebo (n=1283) | NYHA III,IV | double blind Parallel groups Sample size: 2550/1283 Primary endpoint: Total mortality FU duration: 9 months | | VSG, 1993 | Vesnarinone 60mg/d (n=-9) vs. placebo (n=-9) | NYHA II-IV | double blind Parallel groups Sample size: -9/-9 Primary endpoint: total mortality or major cardiovascular morbidity FU duration: 6 months |
|
